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Selective laser sintering (SLS), a rapid prototyping technology, was investigated for producing bone 
tissue engineering scaffolds. Totally biodegradable, osteoconductive calcium phosphate (Ca-
P)/poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) scaffolds were successfully fabricated via SLS 
using Ca-P/PHBV nanocomposite microspheres. In the SLS manufacturing route, the architecture of 
tissue engineering scaffolds (pore shape, size, interconnectivity, etc.) can be designed and the sintering 
process can be optimized for obtaining scaffolds with desirable porous structures and mechanical 
properties. SLS was also shown to be very effective in producing highly complex porous structures 
using nanocomposite microspheres. To render SLS-formed Ca-P/PHBV scaffolds osteoinductive, 
recombinant human bone morphogenetic protein-2 (rhBMP-2) could be loaded onto the scaffolds. For 
achieving a controlled release of rhBMP-2 from scaffolds, surface modification of Ca-P/PHBV 
scaffolds by gelatin entrapment and heparin immobilization was needed. The immobilized heparin 
provided binding affinity for rhBMP-2. Surface modified Ca-P/PHBV nanocomposite scaffolds loaded 
with rhBMP-2 enhanced the proliferation of human umbilical cord derived mesenchymal stem cells 
(hUCMSCs) and also their alkaline phosphatase activity. In in vivo experiments using a rabbit model, 
surface modified Ca-P/PHBV nanocomposite scaffolds loaded with rhBMP-2 promoted ectopic bone 
formation, exhibiting their osteoinductivity. The strategy of combining advanced scaffold fabrication, 
nanocomposite material and controlled growth factor delivery is promising for bone tissue 
regeneration. 
Keywords: bone tissue engineering, scaffold, selective laser sintering, nanocomposite, growth factor, 
controlled release.
1.   Introduction 
Tissue engineering emerged two decades ago, holding 
the promises of providing long-term solutions in 
human body tissue repair and potentially offering 
treatments for medical conditions that are currently 
untreatable [1]. For bone tissue repair, combining 
biodegradable materials (in the form of porous 
scaffolds) with living cells and/or bioactive 
component(s) for bone regeneration provides an 
alternative to autologous bone grafts, the gold standard 
in current orthopaedic surgery, and allogenous bone 
grafts [2]. In scaffold-based bone tissue engineering, 
scaffolds play an important role by mimicking the 
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structure and functions of the extracellular matrix 
(ECM) of the tissue and by providing an 
interconnected porous structure for new bone 
formation and vascularization [3]. Bone is a natural 
nanocomposite material and therefore nanocomposites 
consisting of a biodegradable polymer matrix and 
nanosized osteoconductive fillers such as bioceramics 
and bioglasses can be used to construct bone tissue 
engineering scaffolds [4], enhancing bone tissue 
formation. Furthermore, controlled growth factor 
delivery using the scaffolds as delivery vehicles can be 
employed to promote bone regeneration. Owing to 
their short half-lives, rapid degradation rate, relatively 
large size and slow tissue penetration, direct 
therapeutic applications of growth factors have been 
limited [5]. Using scaffolds for the controlled delivery 
of growth factors can overcome the problems. The 
generally adopted strategies for incorporating growth 
factors into scaffolds include encapsulation in the 
scaffold, physical adsorption and chemical 
immobilization on pore surfaces of scaffolds [6, 7]. 
Rapid prototyping (RP) techniques are matured 
manufacturing technologies which have been widely 
used in traditional industries during the design process 
[8]. RP comprises a group of technologies that can 
generate a physical model directly from computer-
aided design data in a layer-by-layer manner and each 
layer is in the shape of the cross-section of the model 
at a specific level [9]. From the traditional industries, 
RP techniques were first borrowed and employed for 
medical applications when they were used to produce 
accurate models or prosthesis for surgical planning and 
simulation [10, 11]. With the emergence and 
development of tissue engineering, various 
biomaterials and RP techniques are being investigated 
to specifically fabricate porous scaffolds with 
controlled architectures (pore size, shape, 
interconnectivity, geometry and orientation, etc.) and 
properties, targeting at the regeneration of different 
tissues [12-15]. The advantages of RP techniques over 
conventional scaffold fabrication methods include, but 
not limited to, achieving well defined external and 
internal architectures of the scaffolds, computer 
controlled manufacturing processes, and high accuracy 
and reproducibility. Therefore, more and more RP 
techniques are now investigated, developed and 
commercialized for tissue engineering scaffold 
fabrication utilizing biocompatible and biodegradable 
materials as raw materials. 
In the current investigation, selective laser sintering 
(SLS), which is an established RP technology, was 
employed to fabricate three-dimensional (3D) 
nanocomposite scaffolds using calcium phosphate (Ca-
P)/poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) 
nanocomposite microspheres. The surface of Ca-
P/PHBV nanocomposite scaffolds was modified 
through physical entrapment of gelatin and then 
immobilization of heparin in order to provide growth 
factor binding sites. The surface modified scaffolds 
were subsequently loaded with recombinant human 
bone morphogenetic proteins-2 (rhBMP-2). The 
effects of surface modification and rhBMP-2 on 
osteogenic differentiation of human umbilical cord 
derived mesenchymal stem cells (hUCMSCs) were 
studied. Bone tissue regeneration using rhBMP-2 
loaded nanocomposites was investigated using a rabbit 
model. 
2.   Materials and Methods 
2.1.   Fabrication of Ca-P/PHBV nanocomposite 
microspheres 
SLS requires powdered raw materials with appropriate 
particle sizes. Therefore, Ca-P/PHBV nanocomposite 
microspheres consisting of Ca-P nanoparticles and 
PHBV matrix were firstly fabricated. As shown in 
Figure 1A, Ca-P nanoparticles were synthesized in-
house by rapid mixing of Ca(NO3)24H2O acetone 
solution with aqueous (NH4)2HPO4 solution [16]. With 
sizes in the range of 10-30 nm, the Ca-P nanoparticles 
synthesized were amorphous and had a Ca:P molar 
ratio of 1.49. PHBV with 12 mol% 3-hydroxyvalerate 
was from ICI, UK. As shown in Figure 1B, the Ca-
P/PHBV nanocomposite microspheres were prepared 
using a solid-in-oil-in-water (S/O/W) emulsion solvent 
evaporation method [17]. Their Ca-P content was 12.9 
wt% (targeting at 15 wt%), as was determined through 
thermal gravimetric analysis (TGA). 
2.2.   Design and fabrication of 3D 
nanocomposite scaffolds 
A modified Sinterstation2000 system (3D Systems, 
Valencia, CA, USA), as shown in Figure 1C, was used 
for selective laser sintering of scaffolds or porous 
structures. The modification of the SLS machine for  
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scaffold fabrication was reported previously [18]. In 
order to assess the capability of SLS in constructing 
porous structures/scaffolds of complex shapes and 
architecture, four complex models (Figure 2A) 
designed by Hart [19] were employed for producing 
porous structures via SLS. Simple porous scaffold 
models with 3D periodic architectures (e.g., Figure 
3A, Figure 4A and Figure 7A) were designed using 
SolidWorks for different purposes. For optimizing 
pore size, three scaffold models with similar scaffold 
architecture but different pore sizes, as shown in 
Figure 3A, were designed and their dimensions are 
listed in Table 1. 
 
The designs were exported into an STL format and 
transferred to the SLS machine for scaffold 
production. According to our previous optimization 
results, the laser power was set at 15 W and the scan 
spacing and layer thickness were 0.1 mm and 0.1 mm, 
respectively. The part bed temperature, scan speed and 
roller speed were 35 C, 1257 mm/s, and 127 mm/s, 
respectively. 
2.3.   Scaffold surface modification 
The surface modification of rod-shaped sintered 
scaffolds was conducted in two steps: (1) physical 
entrapment of gelatin, and (2) heparin immobilization. 
The physical entrapment of gelatin was achieved by 
immersing sintered Ca-P/PHBV scaffolds (two layers, 
~70 mg/each scaffold) into a gelatin (Sigma, USA) 
solution, which used a miscible mixture of 2,2,2-
trifluoroethanol (TFE; Acros, Belgium) and distilled 
water (TFE:water=30:70), at room temperature for 6 
hr. After the treatment, the scaffolds were rinsed in 
distilled water three times to remove non-entrapped 
gelatin and the dried at room temperature. The amount 
of gelatin entrapped on the scaffold surface was 
determined by bicinchoninic acid (BCA; Pierce, 
Rockford, IL, USA) kit assay. For heparin 
immobilization, gelatin-entrapped Ca-P/PHBV 
 
Fig. 1. Manufacturing process for Ca-P/PHBV nanocomposite scaffolds: (A) synthesis of Ca-P 
nanoparticles; (B) fabrication of Ca-P/PHBV nanocomposite microspheres using the S/O/W emulsion 
solvent evaporation method; (C) principle of SLS and a modified commercial Sinterstation2000 SLS 
system for scaffold fabrication. 












1 8.08.015.5 1.01.01.0 0.5 67.9 
2 8.38.313.5 0.80.80.8 0.5 52.7 
3 8.28.211.5 0.60.60.6 0.5 38.0 
    * Excluding the base. 
    ** Theoretical porosity according to scaffold design. 
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scaffolds were first prewetted in 2-(N-
morpholino)ethanesulfonic acid (MES) buffer solution 
(0.1 M, pH 5.6; Fluka, USA) for 30 min at room 
temperature. 3 mg of heparin (Mw=17,000, activity 
170USP units/mg; Sigma, USA) were dissolved in 1 
ml MES buffer solution (0.1 M, pH5.6) containing 2 
mg N-hydroxysuccinimide (NHS; Sigma, USA) and 
1.2 mg 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide hydrochloride (EDC; Sigma, USA). 
After 4 hr activation at room temperature, the 
prewetted scaffolds were soaked in the activated 
heparin solution in MES buffer for another 4 hr and 
then extensively washed with phosphate buffered 
saline (PBS) and dried overnight at room temperature. 
The amount of heparin conjugated to the surface of 
gelatin entrapped scaffold was determined using the 
toluidine blue method. 
2.4.   Characterization 
The morphology of sintered scaffolds was examined 
using scanning electron microscopes (LEO 1530 FE-
SEM or Hitachi S-3400N SEM) and the porosity of 
scaffolds was measured using a density kit and an 
electronic balance on the basis of Archimedes 
principle. For mechanical testing, sintered, four-
layered scaffold samples were used. Compression tests 
were performed using an Instron 5848 MicroTester 
and the crosshead speed was set at 1.0 mm/min. 
Due to the high porosity of scaffolds designed and 
sintered, instead of using sintered scaffolds, the 
hydrophilicity of scaffold surface before and after 
surface modification was studied by measuring contact 
angles of distilled water droplets on PHBV films 
which were produced using the solvent-casting 
method. The surface modification of solvent-cast 
PHBV films adopted the same procedure as described 
in previous sections. A contact angle machine 
(SL200B, Solon Tech, Co., Ltd., Shanghai, China) 
equipped with an image analyzing system was used 
and water contact angles were measured at room 
temperature using the sessile drop technique. 
2.5.   In vitro biological study 
2.5.1.   Culture of hUCMSCs 
hUCMSCs were provided by Allianceslls Bioscience 
Co., Beijing, China. In cell culture, after reaching 80% 
confluence, cells were digested and subcultured using 
0.25 % (w/v) trypsin-ethylenediamineteraacetic acid 
(EDTA) (Invitrogen, USA). The resulting cells in a 
suspension were seeded separately onto two-layered 
scaffolds which had been sterilized by 
60Co γ-
irradiation. For control experiments, polystyrene tissue 
culture plates (TCPs) were used. Cell seeding onto 
samples was conducted by dripping 100 l cell 
suspension (5×10
6
 cells/ml) in 24-well plates and the 
culture wells were filled with 1 ml of culture medium 
after 2 hr in the incubator. 
2.5.2.   Cell morphology 
After 21 day culture in an osteogenic medium (the 
basal medium supplemented with 10 nM 
dexamethasone, 0.05mM L-ascorbic acid, and 
0.01mM -glycerophosphate.), cell-scaffold constructs 
were harvested, washed with PBS and fixed with 2.5% 
glutaraldehyde at 4 C for 4 hr. After washing with 
cacodylate buffer containing 0.1M sucrose, they were 
dehydrated through a series of graded alcohol 
solutions and dried in a critical point dryer using liquid 
carbon dioxide as the transition fluid. The samples 
were coated with a thin layer of gold before SEM 
examination. 
2.5.3.   Cell proliferation 
After cell culture of 1, 4 and 7 days in a basal medium 
(DMEM/F12), the proliferation of hUCMSCs on Ca-
P/PHBV scaffolds with and without surface 
modification were determined using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. At these time points, the culture 
medium was removed and cell-scaffold constructs 
were washed with PBS to remove non-adhering cells. 
Culture medium with MTT solution (5 mg/ml in PBS) 
was added to each cell-scaffold sample, followed by 
incubation for 4 hr at 37 C. After removal of the 
medium, the formazan crystals formed were dissolved 
in dimethyl sulfoxide (DMSO) and the absorbance was 
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measured using a spectrophotometer at the wavelength 
of 570 nm. 
2.5.4.   Osteogenic differentiation 
For studying the osteogenic differentiation of 
hUCMSCs on the scaffolds, four groups of scaffold 
samples were used: Ca-P/PHBV scaffolds, Ca-
P/PHBV scaffolds with rhBMP-2, Ca-P/PHBV 
scaffolds with surface modification, and surface 
modified Ca-P/PHBV scaffolds with rhBMP-2. For 
incorporating rhBMP-2, 5 g rhBMP-2 were loaded 
onto each scaffold with and without surface 
modification by dripping 50 l rhBMP-2 solutions 
with 20 mM glacial acetic acid and 0.1% bovine serum 
albumin (BSA). 
2.5.5.   Alkaline phosphatase (ALP) activity 
The ALP activity was measured after 7, 14 and 21 day 
cell culture after osteogenic induction. Cell-scaffold 
constructs were rinsed with PBS to remove non-
adhering cells. They were treated with 200 l trypsin 
solution to detach cells. 500 l culture medium were 
then added to end the digestion. After centrifugation at 
5000 rpm for 5 min and further wash with PBS, the 
cells obtained were kept in 500 l lysis buffer 
containing 0.1% (v/v) Triton X-100, 1 mM MgCl2, and 
20 mM Tris, followed by a freezing and thawing 
process to further disrupt the cell membrane. 50 l 
lysate were mixed with 200 l ALP substrate solution 
containing p-nitrophenyl phosphate (pNPP) (Sigma, 
USA) at 37 °C for 30 min. The reaction was stopped 
by the addition of 50 l of 3 N NaOH. The production 
of p-nitrophenol in the presence of ALPase was then 
measured by monitoring the solution absorbance at 
405 nm using a microplate reader. The total protein 
content was determined using BCA assay kit and the 
ALP activity was expressed as mol of p-nitrophenol 
formation per minute per milligram of total proteins 
(mol/min/mg). 
2.6.   In vivo study for ectopic bone formation 
using a rabbit model 
2.6.1.   Animal and surgical procedure 
The in vivo study of Ca-P/PHBV scaffolds with or 
without rhBMP-2 was performed using a rabbit model. 
All treatments and surgical procedures complied with 
the Regulation of Laboratory Animal Unit of the 
University of Hong Kong. Mature male New Zealand 
white rabbits weighing 3.5 kg to 4.0 kg were used. 
Prior to surgery, the rabbits were anaesthetized by 
intramuscular injection of a combination of ketamine 
(35 mg/kg), xylazine (5 mg/kg) and acepromzine (1 
mg/kg). One dose of cephalexin (15 mg/kg) was also 
subcutaneously injected as an antibiotic before 
operation. The surgical site was shaved and disinfected 
with betadine and draped well by sterilized towel. A 
muscle-pocket in the left side along the posterior 
superior iliac spine and the lateral cortex of the ilium 
was carefully prepared, The surface modified scaffold 
loaded with rhBMP-2 was inserted in this pocket and 
then fully wrapped by muscle tissue (Figure 7B). The 
procedure was repeated on the right side of the rabbit, 
inserting the scaffold without surface modification and 
rhBMP-2 in the muscle-pocket. After operation, the 
general health and weight-bearing status of rabbits 
were monitored during recovery. The animals were 
sacrificed after 6 weeks and 12 weeks of surgery, 
respectively, by intravenous injection of a lethal dose 
of pentobarbital, and the scaffolds with surrounding 
tissues were explanted for subsequent experiments. 
2.6.2.   Histological evaluation 
All samples harvested were fixed in 10% buffered 
formalin for 3 days and then rinsed in running water 
for 2 hr. After further dehydration in a graded series of 
ethanol and subsequent immersion in xylene, the 
samples were embedded in polymethylmethacrylate 
(PMMA). The embedded samples were cut into 
sections with a thickness of about 200-300 m by an 
EXAKT 300 CP Band System (Norderstedt, Germany) 
and micro-grounded down to 50-70 m thick using an 
EXAKT 400 CP Micro Grinding System (Norderstedt, 
Germany). The thin samples were stained with 
giemsa-eosin and viewed under a light microscope 
(Nikon H600L, Japan). 
2.7.   Statistical analysis 
All data were obtained from triplicate samples and 
expressed as the mean ± standard deviation (SD). 
Statistical analysis was performed using ANOVA with 
a Scheffé test. A value of p<0.05 was considered to be 
6 Author’s Name 
statistically significant and p<0.01 remarkably 
significant. 
3.   Results 
3.1.   Design and fabrication of scaffolds 
SLS employs a CO2 laser to selectively sinter thin 
layers of powdered polymers or their composites and 
form solid 3D objects. Therefore, Ca-P/PHBV 
nanocomposite microspheres, which served as the raw 
material for scaffold construction via SLS, were first 
fabricated. With sizes of 10-30 nm, the Ca-P 
nanoparticles synthesized (Figure 1A) were 
amorphous and had a Ca:P molar ratio of 1.49. Ca-
P/PHBV nanocomposite microspheres based on Ca-P 
nanoparticles and biodegradable PHBV were produced 
using the S/O/W emulsion-solvent evaporation method 
(Figure 1B). In previous investigations, the 
distribution of Ca-P nanoparticles inside 
nanocomposite microspheres was studied [16]. 
Nanocomposite microspheres were embedded in an 
epoxy resin and then sectioned using a microtome. The 
cross-sectional view of Ca-P/PHBV nanocomposite 
microspheres were obtained through SEM and the 
distributions of calcium and phosphorus in the cross-
sections were conducted using energy dispersive X-ray 
spectroscopy (EDX). It was observed that calcium and 
phosphorus elements were homogeneously distributed 
in the cross-section, indicating the homogeneous 
encapsulation of Ca-P nanoparticles in nanocomposite 
microspheres. Transmission electron microscopy 
(TEM) was also used to study the morphology and 
microstructure of Ca-P/PHBV nanocomposite 
microspheres. Apart from the encapsulation of Ca-P 
nanoparticles inside the microspheres, some 
agglomerated Ca-P nanoparticles were embedded on 
the microsphere surface. In the current investigation, 
PHBV microspheres were also made. Both PHBV and 
Ca-P/PHBV microspheres were of suitable sizes for 
the SLS technology. For sintering Ca-P/PHBV 
nanocomposite scaffolds, a miniature sintering 
platform containing two small powder supply tanks 
and one small build cylinder tank was designed and 
installed in the build cylinder of existing 
Sinterstation2000 system [18], as shown in Figure 
1C. This SLS machine modification significantly 
reduced the consumption of raw material for scaffold 
fabrication. 
In order to verify the optimized values of SLS 
parameters for Ca-P/PHBV scaffolds and investigate 
the fabrication of scaffolds with possible complex 
porous structures, Ca-P/PHBV porous structures with 
complex shapes and architectures were made via SLS. 
Using the four complex models designed by Hart for 
SLS (Figure 2A), four Ca-P/PHBV structures were 
sintered and are displayed in Figure 2B. It can be seen 
that provided that optimized values of SLS parameters 
were used, intricate porous structures with complicated 
shapes could be made via SLS and Ca-P/PHBV 
microspheres could be used for these structures. The 
unsintered, loose Ca-P/PHBV microspheres in the 
  
Fig. 2. Fabrication of complex porous structures via SLS: (A) four 
models designed by Hart for SLS [19], (a) Tangled Reindeer; (b) 
Salamanders; (c) Snarl and (d) elevated cosidodecahedron; (B) Ca-




Fig. 3. Fabrication of scaffolds via SLS: (A) designed scaffold 
models with different pore sizes; (B) Ca-P/PHBV nanocomposite 
scaffolds produced, (a) Type 1, (b) Type 2, (c) Type 3; and SEM 
images of sintered Ca-P/PHBV nanocomposite scaffolds with 
different pore sizes: (C) Type 1, (D) Type 2, (E) Type 3. (Scale bar: 
200 m). 
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structures were removed easily from the structures by 
gentle shaking. Furthermore, the sintered structures 
were robust, capable of withstanding the routine 
handling force without any damage. 
3.2.   Scaffold characteristics and selection of 
pore size 
Three similar scaffold models with different pore size 
(0.6 mm, 0.8 mm and 1.0 mm) were designed (Figure 
3A and Table 1). All models included one solid base 
and a ten-layer scaffold in the z-direction. In order to 
keep the cross-section areas that were occupied by 
scaffold struts comparable among the three types of 
scaffolds, there were different scaffold layers in the x-
direction and y-direction (5 layers for Type 1, 6 layers 
for Type 2 and 7 layers for Type 3). Ca-P/PHBV 
scaffolds were successfully sintered based on these 
three models and are shown in Figure 3B. The 
measured porosity values of Type 1 and Type 2 
scaffolds produced were 80.7±0.7% and 62.6±1.2%, 
respectively, which were larger that those of 
theoretical values listed in Table 1 (67.9% for Type 1 
and 52.7% for Type 2). However, the porosity of Type 
3 scaffolds produced was 36.9±1.4%, which was 
smaller than that of the theoretical value (38.0%). 
The typical layer morphology of SLS-formed Ca-
P/PHBV nanocomposite scaffolds, which had the same  
designed strut size (0.5 mm) but different designed 
pore sizes, is shown in Figure 3C to 3E. For sintered 
Type 1 and Type 2 scaffolds (with the designed pore 
size of 1.0 mm and 0.8 mm, respectively), the pores 
were clearly identified and the pore size and strut size 
were comparable to those of the design. Similarly, 
both macropores of the design and micropores existing 
between fully sintered microspheres were observed. 
However, for Type 3 scaffolds (with the designed pore 
size of 0.6 mm), the observed pore size was much 
smaller than the design. As expected, the mechanical 
properties increased with decreasing pore size. The 
compressive strength and modulus of Type 1 scaffolds 
were 0.24±0.02 MPa and 3.96±0.64 MPa, 
respectively. With decreasing pore size, the 
compressive strength of Type 2 and Type 3 scaffolds 
increased to 0.55±0.09 MPa and 0.89±0.22 MPa, 
respectively, with the modulus reaching 6.41±1.77 
MPa and 13.68±1.02 MPa, respectively. The increase 
of mechanical properties for Type 3 scaffolds was due 
not only to the decrease in pore size but also to the 
entrapped microspheres. Considering the requirement 
of pore size for bone tissue engineering, quality of 
sintered scaffolds and their mechanical properties, Ca-
P/PHBV nanocomposite scaffolds with the designed 
pore size of 0.8 mm were fabricated and used in 
subsequent in vitro and in vivo studies. 
3.3.   Surface modification of Ca-P/PHBV 
scaffolds 
A 3D periodic porous scaffold model was designed for 
the surface modification study and Ca-P/PHBV 
nanocomposite scaffolds were fabricated via SLS 
(Figure 4A). (The rod-shaped scaffold models 
consisted of a repeating array of struts with diameter 
of 1.0 mm in the three principal directions and the 
distance between each strut was set at 1.8 mm.) Under 
SEM at high magnifications, both necking of 
microspheres and intact microspheres without fusion 
were observed (Figure 4B). The porosity of sintered 
scaffolds was measured to be 61.8±1.2%, which was 
also higher than the theoretic porosity value (53.5%). 
For surface modification, the entrapment of gelatin 
was first conducted, which involved the use of a 
 
Fig. 4. Surface modification of scaffolds: (A) rod-shaped Ca-
P/PHBV nanocomposite scaffolds for surface modification, design 
model (left) and sintered scaffold (right); (B) SEM image of the 
strut surface of a sintered Ca-P/PHBV nanocomposite scaffold; (C) 
water contact angle images for (a) PHBV film; (b) gelatin entrapped 
PHBV film; and (c) gelatin entrapped, heparin immobilized PHBV 
film. 
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miscible mixture of solvent and non-solvent for the 
PHBV matrix. During the entrapment process, the 
PHBV matrix swelled but did not dissolve in the 
gelatin solution. The gelatin molecules then diffused 
onto the swollen surface of PHBV and were entangled 
with PHBV molecules on the surface. After the 
scaffold was removed from gelatin solution and 
immersed in water, which is a non-solvent for the 
polymer, the surface rapidly shrank and gelatin 
molecules on the polymer surface were entrapped and 
immobilized. This method was also employed by 
others [20]. The amount of entrapped gelatin was 
1955.8±62.1 g/scaffold, as measured by the BCA kit. 
After gelatin entrapment, heparin was covalently 
coupled to amine groups of entrapped gelatin 
molecules. Using the Toluidine blue method, which is 
a facile and qualitative way to verify and determine the 
presence of conjugated heparin [21], a uniform blue 
colour caused by toluidine blue staining was observed 
on the scaffold surface and the amount of immobilized 
heparin was determined to be 41.78±0.39 g heparin 
per scaffold. Pore surfaces inside the scaffolds were 
believed to be uniformly modified by gelatin 
entrapment and heparin immobilization. 
The surface modification did not affect the surface 
morphology of sintered Ca-P/PHBV nanocomposite 
scaffolds. Solvent-cast PHBV films were used instead 
of scaffolds for water contact angle measurement due 
to the high porosity of scaffolds. As shown in Figure 
4C, the water contact angle of PHBV films decreased 
drastically after surface modification. It was changed 
from 93.61±1.85° prior to surface modification to 
75.12±3.79° after gelatin entrapment. Therefore, the 
gelatin entrapment could improve the hydrophilicity of 
PHBV (and hence the scaffolds). After immobilization 
of heparin, the water contact angle was further reduced 
to 72.06±0.89°. 
3.4.   In vitro biological evaluation 
Figure 5 shows representative cell morphology on Ca-
P/PHBV nanocomposite scaffolds with and without 
surface modification. Obviously, hUCMSCs became 
confluent on the sintered scaffolds after 21 day culture 
and covered all scaffold surfaces. From the high 
magnification examination of cell-scaffold construct 
surfaces, it was observed that hUCMSCs spread well 
and anchored themselves onto the nanocomposite 
microspheres of scaffold struts (Figure 5B and 5D). 
The proliferation of hUCMSCs cultured on Ca-
P/PHBV scaffolds with and without surface 
modification was quantified using MTT assay and the 
results are displayed in Figure 6A. The absorbance for 
all samples increased from day 1 to day 7, indicating 
the trend of cell proliferation on all substrates. In the 
early cell culture period, Ca-P/PHBV nanocompoiste 
scaffolds with surface modification showed 
significantly higher cell proliferation (p<0.01 on day 1 
and p<0.05 on day 4) than the scaffolds without 
surface modification. At day 7 of cell culture, no 
significant difference in cell proliferation was 
observed between scaffolds with and without surface 
modification. 
After cell culture in the osteogenic medium, the 
ALP activity of hUCMSCs seeded on the four types of 
scaffolds, namely, Ca-P/PHBV scaffolds, surface 
modified Ca-P/PHBV scaffolds, Ca-P/PHBV scaffolds 
with rhBMP-2, and surface modified Ca-P/PHBV 
scaffolds with rhBMP-2, were analyzed and the results 
are presented in Figure 6B. For all types of scaffolds, 
in general, the ALP activity increased between day 7 
and 14 and reached the maximum at day 14, indicating 
osteogenic differentiation. Cells on surface modified 
scaffolds loaded with rhBMP-2 exhibited the highest 
enzyme activity. They showed significantly higher 
ALP expression than those seeded on scaffolds with 
simple adsorption of rhBMP-2 on day 7 and day 21 
 
Fig. 5. Morphology of hUCMSCs cultured on Ca-P/PHBV 
nanocomposite scaffolds with or without surface modification for 21 
days: (A, B) scaffold without surface modification; (C, D) scaffold 
with surface modification. (A, C: general view; B, D: close view. 
Scale bar: 50 m) 
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(p<0.05 on day 7 and p<0.01 on day 21). Without the 
presence of rhBMP-2, no significant difference in ALP 
was observed between the scaffolds with and without 
surface modification. The ALP activity on scaffold 
samples, as well as tissue culture plates (the positive 
control), decreased on day 21, which is because ALP 
is an early marker for osteogenic differentiation and its 
activity usually peaks at the early stage of 
differentiation 
3.5.   Ectopic bone formation 
After 6 week and 12 week implantation, 
nanocomposite scaffolds implanted in the muscles of 
rabbits were collected and are shown in Figure 7C and 
7D. Six weeks after implantation, no obvious bone 
formation was observed for both simple Ca-P/PHBV 
scaffold and Ca-P/PHBV scaffold loaded with rhBMP-
2 (Figure 7C). Twelve weeks after implantation, only 
soft tissue was observed around Ca-P/PHBV scaffold 
without rhBMP-2. In contrast, the Ca-P/PHBV 
scaffold loaded with rhBMP-2 was surrounded by 
bony tissue (Figure 7D). 
The representative histological images of tissue-
scaffold samples are shown in Figure 7E and 7F. 
These images were obtained from samples after 12 
week implantation and were stained with giemsa-
eosin. (Scaffolds after 6 week implantation were 
encapsulated by the fibrous connective tissue rather 
than bone and the data are not shown in this paper.) At 
12 weeks, the formation of new bone, stained as the 
pink color in Figure 7F, was observed in the Ca-
P/PHBV scaffold loaded with rhBMP-2, whereas, as 
 
Fig. 6. In vitro cell culture study: (A) MTT assay results for cell 
proliferation of hUCMSCs on the Ca-P/PHBV nanocomposite 
scaffolds with or without surface modification; (B) ALP 
activity of hUCMSCs seeded on different scaffolds and tissue 
culture plate (the control) for different culture times. (*p < 0.05; 
**p < 0.01) 
 
 
Fig. 7. In vivo study of Ca-P/PHBV nanocomposite scaffolds: A: 
Scaffold model for the in vivo study (dimensions in mm), (a) top 
view, (b, c) side views, (d) trimetric view; B: Implantation of a 
scaffold in the muscle pocket in a rabbit; C, D: Harvested samples 
after intramuscular implantation in rabbits for different times (Left: 
Ca-P/PHBV nanocomposite scaffold; right: surface modified Ca-
P/PHBV nanocomposite scaffold loaded with rhBMP-2), (C) 6 
weeks, (D) 12 weeks; E, F: histological images of different 
scaffolds after 12 week intramuscular implantation in rabbits, (E) 
Ca-P/PHBV nanocomposite scaffold, (F) surface modified Ca-
P/PHBV nanocomposite scaffold loaded with rhBMP-2. 
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expected, the simple Ca-P/PHBV scaffold did not 
induce any bone formation. The bony tissue also grew 
into the pores of rhBMP-2 loaded scaffolds. 
4.   Discussion 
The current investigation firstly demonstrated the 
success of the strategies adopted, viz., forming the Ca-
P/PHBV nanocomposite as a scaffold material for 
bone tissue engineering and using the SLS technique 
to fabricate 3D nanocomposite scaffolds with 
controlled porous structure and properties. The Ca-
P/PHBV nanocomopsite consists of a PHBV matrix, 
which is a well-established biodegradable polymer for 
medical applications, and nano-sized Ca-P particles. 
Scaffolds made of this composite mimic the structure 
and functions of bone ECM to support expanded cells, 
which will secrete their own ECMs, replacing the 
biodegradable scaffolds with new bone tissue. Another 
advantage of the current processing route, as compared 
to the dry-blending method adopted by some 
researchers in preparing SLS raw materials, is that the 
bioceramic nanoparticles can be homogeneously 
distributed in the polymer matrix of composite 
scaffolds. In addition, using this processing route, 
some drugs or even biomolecules can be incorporated 
into the microspheres (and hence the scaffolds after 
SLS) in order to expand the functions of the scaffolds. 
Using various simple or complex models (Figure 2A, 
3A, 4A and 7A), robust Ca-P/PHBV nanocomposite 
scaffolds and porous structures were successfully 
produced, which had comparable features as the 
design models. The current investigation has thus 
demonstrated that according to specific requirements 
and designs, osteoconductive bone tissue engineering 
scaffolds can be made via SLS using the Ca-P/PHBV 
nanocomposite microspheres. 
During bone regeneration, characteristics of pores 
in scaffolds are of significant importance because the 
pores allow migration and proliferation of osteoblasts 
and mesenchymal cells, as well as vascularization 
[22]. Conflicting data exist in the open literature with 
regard to the effects of pore size, size distribution and 
porosity on osteogenesis and vascularization. Usually, 
pore sizes in the range of 200 to 900 m are 
considered to be most suitable for synthetic bone 
grafts designed to mimic the architecture of trabecular 
bone [23]. Furthermore, the pore size in scaffolds may 
also influence the type of osteogenesis. Several studies 
on ectopic bone formation using hydroxyapatite 
reported that smaller pore sizes (90-120 m) resulted 
in chondrogenesis before osteogenesis whereas larger 
pore sizes (350 m) resulted in direct osteogenesis 
with enhanced vascularization [24, 25]. From the 
mechanical point of view, structures with smaller pore 
size provide greater mechanical stability in a complex 
mechanical environment. Therefore, a balance is 
needed between a large pore size that allows rapid 
osteointegration and a small pore size that provides the 
ability to bear mechanical loads. In the current 
investigation, a pore size was chosen on the basis of 
bone tissue engineering requirements, resolution of the 
SLS equipment and sintered products. With a large 
design pore size (0.8 mm or 1.0 mm), sintered 
scaffolds (Type 1 and Type 2 scaffolds) had a larger 
porosity than the design value but possessed a lower 
mechanical strength. In contrast, the porosity of 
sintered Type 3 scaffolds was smaller than that of the 
theoretical value. The laser spot size in the 
Sinterstation2000 system, which is determining 
factor for the resolution of sintered products, is about 
457 µm, which is closer to the design pore size of 
Type 3 scaffolds (600 µm). Therefore, the pore size in 
Type 3 scaffolds was not as accurate as those in Type 
1 and Type 2 scaffolds. In addition, the “growth 
effect”, which is a common phenomenon in SLS 
processes, also significantly affects the feature 
dimensions in sintered scaffolds. This phenomenon is 
usually observed in the sintered products with small 
features or small pores due to the penetration of the 
laser energy beyond the theoretical scan area. The 
growth effect had decreased the pore size of Type 3 
scaffolds and thus increased the strut size, resulting in 
a lower porosity than the theoretical value. Normally, 
the entrapped unsintered microspheres were easily 
removed from the Type 1 and Type 2 scaffolds by 
manual shaking. However, for Type 3 scaffolds, the 
entrapped microspheres could not be completely 
removed even with the help of a compressed gas jet. 
Therefore, the design pore size of 0.8 mm for Type 2 
scaffolds was considered as suitable pore size in the 
current investigation on the basis of the pore size 
requirement for bone regeneration, quality of sintered 
scaffolds and their mechanical properties. By 
controlling the architecture of the scaffolds (pore size, 
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interconnectivity, geometry, etc.), the physical, 
mechanical and biological properties of scaffolds such 
porosity and density, strength, degradation and cellular 
response could be controlled. 
In order to improve the bioactivity of sintered 
scaffolds and thus promote bone regeneration, growth 
factors can be incorporated in bone tissue engineering 
scaffolds. For achieving a better control of the growth 
factor release behavior, in the current investigation, 
heparin was immobilized on the surface of gelatin 
entrapped Ca-P/PHBV nanocomposite scaffolds. 
Based on the carbodiimide chemistry, the entrapped 
gelatin provided amino group for the conjugation of 
heparin. Heparin, a sulfated polysaccharide belonging 
to the glycosaminoglycans family, is known to have 
the binding affinity with a number of growth factors 
and is thus capable of blocking the degradation of the 
growth factors and prolonging their release time [26, 
27]. The surface modification by the entrapment of 
gelatin and immobilization of heparin greatly 
decreased the water contact angle of solvent-cast 
PHBV films, indicating the large improvement of 
wettability of surface modified Ca-P/PHBV 
nanocomposite scaffolds. But the morphology and 
mechanical properties of Ca-P/PHBV nanocomposite 
scaffolds were not altered by this surface modification. 
hUCMSCs are a promising cell source for bone 
tissue regeneration due to their inexhaustible supply, 
multilineage differentiation capacity and noninvasive 
harvest procedure. The behavior and fate of stem cells 
are usually regulated by their in vivo 
microenvironment, known as stem cell niche [28]. Key 
niche components and interactions include growth 
factors, cell-cell contacts, and cell-ECM adhesions 
[29]. The role of tissue engineering scaffolds is 
generally to biomimic the natural ECM and to emulate 
stem cell niche in combination with growth factors and 
other signaling. In the current investigation, 3D Ca-
P/PHBV nanocomposite scaffolds with surface 
modification, i.e., gelatin entrapment and heparin 
immobilization, and further loading of rhBMP-2 were 
used to investigate the osteogenic differentiation of 
hUCMSCs. The improvement of wettability resulting 
from the surface modification facilitated the adhesion 
of hUCMSCs at the early stage of cell culture (in 
culture before 7 days) when cells made contact with 
the scaffolds. However, no significant difference was 
observed in ALP activity in the osteogenic 
differentiation of hUCMSCs cultured on Ca-P/PHBV 
nanocomposite scaffolds with and without surface 
modification. The cells cultured on Ca-P/PHBV 
nanocomposite scaffolds with and without surface 
modification became confluent and showed normal 
phenotype after 21 days in the osteogenic medium. 
The main purpose of heparin immobilization on 
scaffolds was to provide specific affinity between 
heparin immobilized scaffolds and growth factors and 
to control the release profile of bound growth factors 
in a sustained manner so as to improve angiogenesis or 
osteogenesis [30, 31]. The ALP activity assay results 
showed that the ALP level was significantly up-
regulated on surface modified Ca-P/PHBV scaffolds 
loaded with rhBMP-2 as compared to that on scaffolds 
with the simple adsorption of rhBMP-2. This clearly 
indicates that the osteogenic differentiation of 
hUCMSCs on scaffolds loaded with rhBMP-2 was 
affected by the way rhBMP-2 was incorporated and 
that it was important to provide immobilized heparin. 
Ectopic bone formation by surface modified Ca-
P/PHBV nanocomposite scaffolds was studied in the 
current investigation using a rabbit model. For 
intramuscular implantation, the Ca-P/PHBV 
nanocomposite scaffolds without rhBMP-2 did not 
induce any bone formation after implantation for up to 
12 weeks. In high contrast, surface modified scaffolds 
loaded with rhBMP-2 stimulated ectopic bone 
formation after 12 week implantation, indicating the 
positive effects of rhBMP-2 release on homologous 
bone formation. The moderate foreign body reaction 
and the absence of necrosis at the implantation site 
indicated that there were no in vivo toxic effects by the 
Ca-P/PHBV nanocomposite scaffolds. The in vivo 
results suggested that the surface modified Ca-
P/PHBV nanocomposite scaffolds loaded with 
rhBMP-2 possessed osteoinductivity and therefore 
could promote bone tissue formation in both non-
osseous and osseous sites in the body. 
5.   Conclusions 
It is feasible to combine the SLS technique, 
nanocomposite approach and sustained release of 
growth factor to form high-performance bone 
engineering scaffolds. Scaffolds and porous structures 
of complex shapes and architecture could be fabricated 
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via SLS. For Ca-P/PHBV nanocomposite scaffolds, 
with decreasing pore size, the porosity of scaffolds 
decreased and the mechanical properties increased. 
Nanocomposite scaffolds with the design pore size of 
0.8 mm were considered to be suitable for bone tissue 
engineering. The surface modification improved the 
wettability of scaffolds and provided binding sites for 
the growth factor rhBMP-2. The ALP activity of 
hUCMSCs on surface modified scaffolds loaded with 
rhBMP-2 was significantly higher than that of the cells 
on scaffolds with simple adsorption of rhBMP-2 
during the 21 day culture period. In in vivo 
experiments using a rabbit model, ectopic bone 
formation by surface modified Ca-P/PHBV scaffolds 
loaded with rhBMP-2 occurred after 12 week 
intramuscular implantation. Integrating SLS for 
scaffold fabrication, osteoconductive nanocomposite 
as scaffold material and controlled growth factor 
delivery provides a very effective strategy for bone 
tissue engineering. 
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